Projects per year
Abstract
Vascular dysfunction is an important hallmark of cardiovascular disease. It is characterized by increased sensitivity to vasoconstrictors, decreases in the endothelium-derived vasodilators nitric oxide (NO) and prostacyclin (PGI2), and endothelium-derived hyperpolarization (EDH). Serelaxin (recombinant human relaxin) has gained considerable attention as a new vasoactive drug, largely through its beneficial therapeutic effects in acute heart failure. In this review we first describe the contribution of endogenous relaxin to vascular homeostasis. We then provide a comprehensive overview of the novel mechanisms of serelaxin action in blood vessels that differentiate it from other vasodilator drugs and explain how this peptide could be used more widely as a therapeutic to alleviate vascular dysfunction in several cardiovascular diseases.
Original language | English |
---|---|
Pages (from-to) | 498-507 |
Number of pages | 10 |
Journal | Trends in Pharmacological Sciences |
Volume | 37 |
Issue number | 6 |
DOIs | |
Publication status | Published - 2016 |
Projects
- 1 Finished
-
Vitamin D deprivation in early life: programming of vascular function in adulthood ID: 334046
Parkington, H., Morley, R., Tare, M. & Wintour-Coghlan, M.
National Health and Medical Research Council (NHMRC) (Australia)
1/01/05 → 31/12/07
Project: Research